PathAI’s Post

Join us for a live webinar on April 24th, The Future of Precision Medicine: Leveraging Clinico-Genomic Data for Germline Disorders. We discuss with #precisionmedicine experts Dr. Christopher O'Donnell from Novartis and Dr. Daniel Judge at Medical University of South Carolina on how linked clinico-genomic data can drive #drugdiscovery and development in the age of precision medicine. Learn about life science use cases and how genetic medicines translate to clinical care in germline disorders. Register here: https://bit.ly/4dcO73I

https://lnkd.in/gY6tFmrj Article title: HPA-3 and C807T polymorphisms are associated with laboratory biomarkers of coronary artery disease in Brazilian women   Author(s): Suellen Pinheiro Carvalho Valverde; Setondji Cocou Modeste Alexandre Yahouédéhou; Rodrigo Mota de Oliveira; Nathalie Souza Veloso; Cleverson Alves Fonseca; Karina Oliveira Mendes; Cynara Gomes Barbosa; Marilda de Souza Gonçalves; Elisângela Vitória Adôrno   Journal: Open Journal of Pain Medicine   Journal ISSN: 2640-8104 Abstract: Reports describe the association between platelet activation, adhesion, and aggregation, as well as polymorphisms in genes encoding platelet membrane glycoproteins with a predisposition to coronary artery disease (CAD). This study investigates associations between HPA-1, -3 and C807T polymorphisms and CAD. A cross-sectional study involving 114 women who underwent coronary angiography was performed. The CAD+ group consisted of 63 women while the CAD- group of 51 women. #CoronaryArteryDisease #PlateletGlycoprotein #Polymorphisms #LaboratoryParameters #PhysiologyOfPain #MechanismsOfPain #AcutePain #ChronicPain #TherapeuticOptions #PainControl #InterventionalProcedures #NonPharmacologicApproaches #PostoperativePain #OncologyPain #PainSyndromes #PalliativeCare #PediatricHealth #AgingHealth #Peertechz #PeertechzPublications #OpenAccess #ScientificJournals #PeerReviewedJournals #OpenAccessPublishers #Pharmacology #Addiction #Abuse #PainMedication #AdverseEvents #DrugSafety #PharmacoeconomicsResearch #QualityOfLife

Our recently published work was designed to estimate the cost-effectiveness of pharmacogenomic-guided treatment in kidney transplant recipients in the Austrian Healthcare Setting. U-PGx Prepare study represents the world's largest scale (7,000 patients), open-label, multicenter, controlled, cluster-randomized crossover implementation study in genomic medicine.  i would like to thank all the participants for the great effort.  #https://lnkd.in/d2zsRWV4  #goldenhelixfoundation hashtag #pharmacogenomics hashtag #costeffectivenessanalysis hashtag #research

🌟 CIMA Sciences, LLC and OWL Metabolomics will attend at the upcoming Emerging Topic Conference: Precision Medicine in MASLD, which is organized by American Association for the Study of Liver Diseases (AASLD) in Las Vegas the 8-9th of March, in which CIMA Sciences, LLC will be sponsoring the coffee break. 🔬 Cristina Alonso, the Metabolomics Services Manager of OWL Metabolomics, will deliver a talk on advances in metabolomics and hepatology. Don’t miss this opportunity! 🤝 Meet us in the event to discover more about OWLiver® non-invasive diagnostic tool and how we're contributing to non-invasive liver health diagnostics to fight #MASH and #MASLD.   #MASEF #Metabolomics #OWLMetabolomics

🔬 Today, on Rare Disease Day, we're proud to shed light on our ongoing collaborative efforts with the University of Zurich to predict drug targets for an ultra-rare lysosomal storage disease called cystinosis. 🤝🌍 “Children with cystinosis suffer from a devastating, multisystemic disease, and there are currently no available curative treatments,” says Olivier Devuyst, head of the Mechanisms of Inherited Kidney Disorders (MIKADO) group and co-director of the ITINERARE University Research Priority Program at UZH. 🎯 UZH researchers have been working with Insilico Medicine to uncover the underlying cellular mechanism behind kidney disease in cystinosis. Leveraging model systems and Insilico’s PandaOmics platform, they identified the disease-causing pathways and prioritised therapeutic targets within cystinosis cells. Their findings revealed a causal association between the regulation of a protein called mTORC1 and the disease. 🧬 Alessandro Luciani, one of the research group leaders, explains: “Our research showed that cystine storage stimulates the activation of the mTORC1 protein, leading to the impairment of kidney tubular cell differentiation and function.” 📚 Read the breakthrough Nature publication here: https://lnkd.in/e63DDBwQ 📖 🌍 If you are engaged in a rare disease project and seek cutting-edge platforms, we extend an invitation to explore the possibilities with Pharma.ai. 💡 Together, we can make a meaningful impact on the landscape of rare disease research. 🌈 Alex Zhavoronkov Alex Aliper Petrina Kamya, Ph.D. Michelle Chen Jan Szollos, MBA Aisyah Jamil, MD, Msc. Ivan Ozerov Frank Pun Jue Wang Kyle Tretina, PhD Brita Belli #RareDiseaseDay #PandaOmics #CystinosisResearch #AIinHealthcare #InnovationInMedicine #Collaboration #PharmaAI #InsilicoMedicine #MIKADOResearch #HealthcareInnovation Note: For more information about this project, please visit https://lnkd.in/gdKuif7j. 

I’m excited to share the work led by Dr Nadhir Yousfi and Prof. Laurent MESNARD, to which I had the privilege of contributing. In this letter to the journal Blood, we show how nanopore sequencing can enable fast genomic testing in cases of adult thrombotic microangiopathies. We describe 18 prospective cases to illustrate the benefits of this approach: ⏱️ Rapid turn-around time: Time to genomic results reduced from the standard 3–8 weeks to less than 3 days. 🧬 Clinical-grade analytical performance: Comparable to standard-of-care short-read sequencing, and in addition, detects highly complex structural variants of complement factor H-related genes (!!). 💊 Clinical impact: Timely, targeted treatment with complement blockade might improve patient outcomes. 💵 Cost-efficiency: Faster diagnostics could also reduce healthcare costs by minimizing unnecessary treatments. This is a great example of the benefits of integrating innovative AND accessible genomic workflows into routine clinical practice, particularly in nephrology and critical care. Read the full publication here: https://lnkd.in/exCKPDWz #Genomics #PrecisionMedicine #ThromboticMicroangiopathy #TMA #NanoporeSequencing #Nephrogenomics #ONT

Sufficient to validate interventions in laboratory settings and then when interventions are validated - as Kenneth Day says - work out more easily measured metrics which correlate with these interventions in biological age reversal. We need to work out what reverses and what increases biological age. Ideally - we'll do this in a much more scientific way and use our heads before we choose what to study. Looking at raw keto veganism to come out on top - raw lemons/berries do wonders for taming inflammation ... inflammaging. Using them now. https://lnkd.in/e25kVA33

#HighlyCitedPapers 📝 Definition of an Inflammatory Biomarker Signature in Plasma-Derived Extracellular Vesicles of Glioblastoma Patients — Cilibrasi et al. In this paper, the authors isolated sEVs from blood liquid biopsies of #glioblastoma patients and characterised their proteomic cargo to identify potential candidate glioblastoma biomarkers. Full text is available 👇 https://lnkd.in/eibmeCcb #medicine #health #research #science

New publication! Use of machine learning to identify cytokine and autoantibody profiles associated with different clinical presentations of systemic lupus erythematosus (SLE). In this pilot study, we use kModes clustering and multiple correspondence analysis (which are essentially kMeans clustering and PCA for categorical data) to automatically stratify patients suffering from SLE based on their autoantibody profiles. We demonstrate unique autoantibody signatures that are associated with lupus nephritis. These patients also have distinct patterns of circulating cytokines, as revealed by a partial least squares discriminant analysis (PLS-DA). Congratulations to all the authors! #lupus #SLE #cytokines https://lnkd.in/dHK3YMZH

🌟 Unlock the future of healthcare with Knowledge Sourcing Intelligence's latest report on the Genomic Medicine Market! 🧬📈 Genomic medicine is revolutionizing the #healthcareindustry by offering personalized #treatment and #precisionmedicine based on an individual's genetic makeup. Our comprehensive report provides valuable insights into #markettrends, growth drivers, key players, and regional dynamics shaping this transformative field. Explore how advancements in #genomics are leading to groundbreaking developments in the diagnosis, treatment, and prevention of diseases. From cancer and rare genetic disorders to infectious diseases, genomic medicine holds the promise of more effective and tailored healthcare solutions. Stay informed and ahead of the curve in this rapidly evolving market. Click the link below to access the full report and discover the opportunities within the Genomic Medicine Market. https://lnkd.in/giHxM-mN #GenomicMedicine #PersonalizedHealthcare #MarketInsights #healthcare #HealthcareInnovation #Genomics 🧬🌐📊